Gene subnetworks predict cancer spread

December 15, 2008

The metastasis or spread of breast cancer to other tissues in the body can be predicted more accurately by examining subnetworks of gene expression patterns in a patient's tumor, than by conventional gene expression microarrays, according to a presentation at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

The subnetworks provide new prognostic markers representing sets of co-functional genes, say scientists at the University of California at San Diego (UCSD), Trey Ideker and Han-Yu Chuang, who worked with Eunjung Lee and Doehaon Lee of the Korean Advanced Institute of Science and Technology in Daejeon, South Korea.

The U.S.-Korea researchers identified the subnetworks by using bioinformatic algorithms to crunch through mountains of gene expression profiles from large cohorts of women with breast cancer.

The data represented women with breast cancer metastasis as well as patients whose tumors had not spread.

The gene expression profiles were then mapped to the extensive networks of signaling pathways and protein complexes in human cells that had been revealed in previous studies.

Searching the data, the researchers identified subnetworks in which aggregate gene expression patterns distinguished one patient group from another.

They also uncovered many genes associated with breast cancer that had not been identified by previous gene microarray profiles.

Thanks to rapid microarray technology, cancers can now be classified according to their gene expression, or activity patterns.

However, disease classification by gene expression is imprecise because cells taken from a single tumor sample often are heterogeneous; genes switched on in cells from one part of the tumor may not be active elsewhere in the tumor.

In addition, the expression profiles from a range of patients with the "same" type and grade of tumor can differ significantly.

Ideker and Chuang's approach may change diagnostics so that a patient's diagnosis could go beyond, for example, estrogen responsive breast cancer to a particular subtype of estrogen responsive breast cancer with poor or good prognosis.

The U.S.-Korean researchers are now extending their new integrated analysis to other cancers including leukemia, prostate cancer and lung cancer.

They are identifying "condition-responsive" genes within signaling and transcriptional pathways that could be used as a measure of activation levels and could provide another useful tool for diagnosis and prognosis, they say.
-end-
For more information: Contact John Fleischman, ASCB science writer, jfleischman@ascb.org, (513) 929-4635, (513) 706-0212, or Cathy Yarbrough, ASCB annual meeting media manager, cyarbrough@ascb.org, (858) 243-1814.

or

Trey Ideker
University of California, San Diego
trey@bioeng.ucsd.edu
(858) 822-4558

Han-Yu Chuang
University of California, San Diego
hchuang@ucsd.edu
(858) 822-4665

The authors will present Poster B B471, titled, "Network-based diagnosis and modelling of cancer development and progression," on Monday, Dec. 15, 1:30 pm, in Program 1261, Bioinformatics/Biological Computing, Halls A-C, Moscone Center.

Authors: H.-Y. Chuang, T. Ideker, Bioinformatics Program and Department of Bioengineering, University of California-San Diego, La Jolla, CA; E. Lee, D. Lee, Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea

American Society for Cell Biology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.